Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5233541 | PMC |
| http://dx.doi.org/10.21037/atm.2016.11.69 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimal Planning Target Volume Margins to Account for Intra-Fractional Prostate Motion Relative to Treatment Duration: A Study Using Real-Time Transperineal Ultrasound Guidance.
J Med Imaging Radiat Oncol
January 2025
Department of Radiation Oncology, Townsville University Hospital, Townsville, Queensland, Australia.
Introduction: Prostate motion during external beam radiotherapy (EBRT) is common and typically managed using fiducial markers and cone beam CT (CBCT) scans for inter-fractional motion correction. However, real-time intra-fractional motion management is less commonly implemented. This study evaluated the extent of intra-fractional prostate motion using transperineal ultrasound (TPUS) and examined the impact of treatment time on prostate motion.
View Article and Find Full Text PDFSystematic Review of Stereotactic Ablative Radiotherapy (SABR)/ Stereotactic Body Radiation Therapy (SBRT) for Treatment of High-Risk Patients with Stage I Non-Small Cell Lung Cancer.
Semin Thorac Cardiovasc Surg
December 2024
Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, and UPMC Hillman Cancer Center. Pittsburgh, PA. Electronic address:
Stereotactic ablative radiotherapy (SABR) has emerged as an alternative, non-surgical treatment for high-risk patients with stage I non-small cell lung cancer (NSCLC) with increased use over time. The American Association for Thoracic Surgery (AATS) Clinical Practice Standards Committee (CPSC) assembled an expert panel and conducted a systematic review of the literature evaluating the results of SABR, which is also referred to as stereotactic body radiation therapy (SBRT) or stereotactic radiosurgery (SRS), prior to developing treatment recommendations for high-risk patients with stage I NSCLC based on expert consensus. Publications detailing the findings of 16 prospective studies of SABR and 14 retrospective studies of SABR for the management of early-stage lung cancer in 54 697 patients were identified by systematic review of the literature with further review by members of our expert panel.
View Article and Find Full Text PDFPartial Stereotactic Ablative Radiotherapy Boost Before Conventional Radiotherapy (P-SABR) for Large (> 5 cm) Unresectable Stage III Nonsmall Cell Lung Cancer.
Thorac Cancer
January 2025
Department of Radiation Oncology, Peking University First Hospital, Beijing, China.
Objective: Stereotactic ablative radiotherapy (SABR) is renowned for its high local control (LC) rates. Nonetheless, for tumors that are either large in volume or in close proximity to critical organs at risk, the application of SABR to the entire tumor becomes impractical. This study aims to evaluate the efficacy and safety of partial SABR boost before conventional radiotherapy (P-SABR) for the treatment of large (> 5 cm) unresectable stage III nonsmall cell lung cancer (NSCLC).
View Article and Find Full Text PDFCosts of stereotactic ablative radiotherapy compared to conventional radiotherapy in the treatment of non-small cell lung cancer - a micro-costing study using Time-Driven Activity Based Costing (TDABC).
BMC Health Serv Res
November 2024
Departamento de Medicina Preventiva, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Av Dr Arnaldo 455, CEP: 01246903, Sao Paulo, SP, Brazil.
Background: Lung cancer is one of the leading causes of morbidity and mortality in Brazil. Radiotherapy is an important therapeutic option, but the techniques used remain subjects of discussion. In this study, we compared the costs of conventional radiotherapy (CRT) and stereotactic ablative radiotherapy (SABR) in the treatment of early-stage non-small cell lung cancer (NSCLC).
View Article and Find Full Text PDFThe TROG 15.01 stereotactic prostate adaptive radiotherapy utilizing kilovoltage intrafraction monitoring (SPARK) clinical trial database.
Med Phys
November 2024
Image X Institute, The University of Syndey, Sydney, Australia.
Article Synopsis
- * The SPARK trial was a phase II study involving 48 patients that utilized KIM technology to monitor real-time tumor movements and evaluate the accuracy of cancer targeting during radiotherapy.
- * The publicly available dataset includes a variety of imaging and treatment data, stored at the University of Sydney eScholarship Repository, which can be used for further research and analysis in the field of radiotherapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!